Medpace MEDP
$610.54 −$23.44 (-3.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $605.49 -0.83%
Open$632.09
Prev close$633.98
Day range$606.73 – $633.87
Volume236.8K
Market cap$17.08B
P/E (TTM)33.9
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$716.00M+8.5% YoY
Operating profit$165.54M+16.7% YoY
Net profit$137.46M+23.7% YoY
Diluted EPS$4.84+25.4% YoY
Free cash flow$196.44M-16.6% YoY
Operating cash flow$216.60M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin29.1%
Operating margin21.4%
Net margin18.2%
Return on equity117.9%
Return on assets25.5%
Return on invested capital90.6%
Current ratio0.83
Liabilities / assets74.6%
Cash & investments$705.32M
Total debt$146.04M
Net cash (debt)$559.27M
Free cash flow / sales23.5%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $716.00M | $707.33M | $706.60M | $2.53B | $708.45M |
| Total Operating Revenue | $716.00M | $707.33M | $706.60M | $2.53B | $708.45M |
| Cost of Revenue | $492.12M | $505.69M | $510.28M | $1.77B | $503.13M |
| Gross Profit | $223.89M | $201.64M | $196.33M | $760.62M | $205.32M |
| Operating Expense | $58.35M | $54.81M | $54.82M | $225.68M | $52.05M |
| Selling and Admin Expenses | $51.77M | $48.10M | $47.92M | $197.56M | $44.92M |
| Depreciation & Amortization & Depletion | $6.58M | $6.71M | $6.91M | $28.12M | $7.13M |
| -Depreciation & Amortization | $6.58M | $6.71M | $6.91M | $28.12M | $7.13M |
| Operating Profit | $165.54M | $146.82M | $141.50M | $534.94M | $153.27M |
| Net Non-Operating Interest Income (Expense) | $5.35M | $4.99M | $5.12M | $12.78M | $3.72M |
| Total Other Finance Costs | -$5.35M | -$4.99M | -$5.12M | -$12.78M | -$3.72M |
| Other Income (Expense) | $17,000.00 | -$147,000.00 | $971,000.00 | -$5.34M | -$158,000.00 |
| Other Non-Operating Income (Expenses) | $17,000.00 | -$147,000.00 | $971,000.00 | $2.39M | $7.57M |
| Pretax Profit | $170.91M | $151.66M | $147.59M | $542.38M | $156.83M |
| Tax | $33.45M | $30.30M | $23.72M | $91.25M | $21.70M |
| Net Profit | $137.46M | $121.36M | $123.87M | $451.12M | $135.13M |
| Profit from Continuing Operations | $137.46M | $121.36M | $123.87M | $451.12M | $135.13M |
| Net Income to Parent Company | $137.46M | $121.36M | $123.87M | $451.12M | $135.13M |
| Other Preferred Stock Dividends | $0.00 | – | – | $0.00 | $0.00 |
| Net Income to Common Stockholders | $137.46M | $121.36M | $123.87M | $451.12M | $135.13M |
| Basic EPS | $4.92 | $4.31 | $4.35 | $15.64 | $4.78 |
| Diluted EPS | $4.84 | $4.25 | $4.28 | $15.28 | $4.67 |
| Gain on Sale of Security | – | – | – | -$7.73M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $2.30B | $2.06B | $2.13B | $1.98B | $1.98B |
| Total Current Assets | $1.25B | $1.05B | $1.14B | $989.62M | $989.62M |
| Cash and Cash Equivalents & Short-Term Investments | $705.32M | $502.69M | $652.68M | $497.05M | $497.05M |
| -Cash and Cash Equivalents | $705.32M | $502.69M | $652.68M | $497.05M | $497.05M |
| Receivables | $447.64M | $441.80M | $394.58M | $402.08M | $402.08M |
| -Accounts Receivable | $419.84M | $420.56M | $370.41M | $376.76M | $376.76M |
| -Other Receivables | $27.83M | $21.27M | $24.20M | $25.35M | $25.35M |
| -Receivables Adjustments Allowances | -$28,000.00 | -$28,000.00 | -$28,000.00 | -$29,000.00 | -$29,000.00 |
| Other Current Assets | $92.04M | $105.80M | $91.79M | $90.50M | $90.50M |
| Total Non-Current Assets | $1.06B | $1.01B | $990.56M | $985.85M | $985.85M |
| Net PPE | $327.55M | $282.96M | $263.36M | $248.87M | $248.87M |
| -Gross PPE | $327.55M | $282.96M | $263.36M | $372.14M | $372.14M |
| Goodwill and Other Intangible Assets | $695.35M | $695.51M | $695.66M | $695.82M | $695.82M |
| -Goodwill | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M |
| -Other Intangible Assets | $32.96M | $33.11M | $33.27M | $33.42M | $33.42M |
| Non-Current Deferred Assets | $3.27M | $3.23M | $3.22M | $19.22M | $19.22M |
| Other Non-Current Assets | $31.42M | $25.20M | $28.32M | $21.94M | $21.94M |
| Total Liabilities | $1.72B | $1.62B | $1.53B | $1.52B | $1.52B |
| Total Current Liabilities | $1.50B | $1.44B | $1.35B | $1.34B | $1.34B |
| Payables | $43.68M | $37.53M | $34.43M | $28.14M | $28.14M |
| -Accounts Payable | $43.68M | $37.53M | $34.43M | $28.14M | $28.14M |
| Current Accrued Expenses | $344.86M | $371.65M | $344.46M | $328.24M | $328.24M |
| Current Deferred Liabilities | $961.86M | $904.72M | $856.34M | $854.39M | $854.39M |
| Other Current Liabilities | $47.23M | $42.10M | $48.18M | $52.83M | $52.83M |
| Total Non-Current Liabilities | $221.56M | $187.89M | $186.29M | $172.65M | $172.65M |
| Long Term Debt and Capital Lease Obligation | $146.04M | $120.10M | $122.26M | $113.64M | $113.64M |
| -Long Term Capital Lease Obligation | $146.04M | $120.10M | $122.26M | $113.64M | $113.64M |
| Non-Current Deferred Liabilities | $13.66M | $8.21M | $3.93M | $1.36M | $1.36M |
| Other Non-Current Liabilities | $61.86M | $59.58M | $60.10M | $57.66M | $57.66M |
| Total Equity | $584.94M | $433.86M | $598.31M | $459.07M | $459.07M |
| Stockholders' Equity | $584.94M | $433.86M | $598.31M | $459.07M | $459.07M |
| Capital Stock | $280,000.00 | $279,000.00 | $286,000.00 | $284,000.00 | $284,000.00 |
| -Common Stock | $280,000.00 | $279,000.00 | $286,000.00 | $284,000.00 | $284,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $978.28M | $964.18M | $953.42M | $935.83M | $935.83M |
| Retained Earnings | -$373.57M | -$511.37M | -$336.11M | -$459.98M | -$459.98M |
| Less: Treasury Stock | -$12.15M | -$12.15M | -$12.16M | -$12.16M | -$12.16M |
| Gains/Losses Not Affecting Retained Earnings | -$7.90M | -$7.08M | -$7.12M | -$4.91M | -$4.91M |
| -Accumulated Depreciation | – | – | – | -$123.27M | -$123.27M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $216.60M | $162.01M | $151.79M | $713.22M | $192.65M |
| Net cash flow from continuing operations | $216.60M | $162.01M | $151.79M | $713.22M | $192.65M |
| Net Income from Continuing Operations | $137.46M | $121.36M | $123.87M | $451.12M | $135.13M |
| Depreciation & Depletion & Amortization | $6.58M | $6.71M | $6.91M | $28.12M | $7.13M |
| Deferred Tax | $5.40M | $4.28M | $18.54M | $80.77M | $17.41M |
| Other Non-Cash Items | $6.58M | $5.91M | $6.25M | $22.14M | $5.24M |
| Change in Working Capital | $52.98M | $19.40M | -$8.70M | $96.28M | $22.12M |
| -Change in Receivables | -$5.79M | -$47.18M | $7.82M | -$106.22M | -$29.10M |
| -Change in Prepaid Assets | $13.37M | -$14.15M | -$1.80M | -$27.10M | -$11.49M |
| -Change in Payables and Accrued Expense | -$6.10M | $44.89M | -$1.22M | $99.71M | $40.90M |
| -Change in Other Current Liabilities | -$5.45M | -$7.06M | -$5.29M | -$25.16M | -$7.03M |
| -Change In Other Working Capital | $56.95M | $42.91M | -$8.22M | $155.04M | $28.84M |
| Net cash flow from investing | -$20.14M | -$23.89M | -$6.75M | -$31.14M | -$4.47M |
| Net Cash Flow from Continuing Investing Activities | -$20.14M | -$23.89M | -$6.75M | -$31.14M | -$4.47M |
| Net Other Investing Changes | $23,000.00 | $26,000.00 | $66,000.00 | $216,000.00 | $63,000.00 |
| Financing Cash Flow | $6.50M | -$288.34M | $12.67M | -$860.39M | $22.73M |
| Net Cash Flow from Continuing Financing Activities | $6.50M | -$288.34M | $12.67M | -$860.39M | $22.73M |
| Net Common Stock Issuance | $0.00 | -$294.76M | $0.00 | -$917.39M | $0.00 |
| Proceeds from Stock Option Exercised | $6.50M | $6.42M | $12.67M | $57.00M | $22.73M |
| Ending Cash Balance | $705.32M | $502.69M | $652.68M | $497.05M | $497.05M |
| Net Change in Cash | $202.96M | -$150.21M | $157.71M | -$178.31M | $210.91M |
| Beginning Cash Balance | $502.69M | $652.68M | $497.05M | $669.44M | $285.35M |
| Effect of Exchange Rate Changes | -$328,000.00 | $221,000.00 | -$2.08M | $5.92M | $790,000.00 |
| Free Cash Flow | $196.44M | $138.10M | $144.97M | $681.87M | $188.12M |
| Capital Expenditure | – | -$23.91M | -$6.81M | – | – |
| Net PPE Purchase and Sale | – | – | – | -$31.36M | -$4.54M |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on MEDP.
Sign in to join the discussion.